ETC
KYMR icon

Exchange Traded Concepts’s Kymera Therapeutics KYMR Stock Holding History

Exchange Traded Concepts’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,693
Closed -$101K – 1467
2025
Q1 		$101K Buy
3,693
+239
+7% +$8.71K ﹤0.01% 1160
2024
Q4 		$139K Hold
3,454
– – ﹤0.01% 1079
2024
Q3 		$163K Sell
3,454
-2,048
-37% -$90.4K ﹤0.01% 1026
2024
Q2 		$164K Sell
5,502
-1,710
-24% -$59.2K ﹤0.01% 897
2024
Q1 		$290K Sell
7,212
-147
-2% -$5.26K 0.01% 810
2023
Q4 		$187K Buy
7,359
+1,866
+34% +$33.4K 0.01% 795
2023
Q3 		$76.4K Buy
5,493
+53
+1% +$1.07K ﹤0.01% 967
2023
Q2 		$125K Buy
+5,440
New +$156K ﹤0.01% 895

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Exchange Traded Concepts's KYMR Position: Q2 2025 in Review

Exchange Traded Concepts sold out of Kymera Therapeutics (KYMR) in Q2 2025, closing a stake of 3,693 shares — an estimated $101K sold.

Exchange Traded Concepts first reported a position in KYMR in Q2 2023 and held it in 8 quarters. The position peaked at $290K in Q1 2024. 210 funds tracked by Wall St. Rank hold KYMR as of Q2 2025.

  • Exchange Traded Concepts reported no remaining Kymera Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 3,693 Kymera Therapeutics shares in Q2 2025, an estimated $101K.
  • Exchange Traded Concepts first reported a position in Kymera Therapeutics in Q2 2023 and held it in 8 quarters.
  • Exchange Traded Concepts's Kymera Therapeutics position peaked at $290K in Q1 2024.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2025.

Based on Exchange Traded Concepts's 13F filing for Q2 2025, filed 10 Jul 2025.